Pressemitteilung BoxID: 379037 (evoxx technologies GmbH)
  • evoxx technologies GmbH
  • Alfred-Nobel-Str. 10
  • 40789 Monheim am Rhein
  • Ansprechpartner
  • Thorsten Eggert
  • +49 (211) 1576095-0

evocatal And EUCODIS Bioscience Enter Into Collaboration Agreement

(PresseBox) (Vienna and Duesseldorf, ) Industrial biotech companies EUCODIS Bioscience and evocatal today announced the formation of an alliance to jointly market the companies' industrial enzyme products, including alcohol dehydrogenases, lipases, and other enzymes.

The two companies will leverage their knowledge of customers' needs in their respective markets as well as their complementary resources to provide existing and future customers with a broader choice of novel enzymes and related services.

Both parties have already started to align their marketing and sales activities, including their product catalogs, and are representing and marketing each partner's products at industry trade fairs, beginning with CPhI 2010, Paris, and Biotechnica 2010, Hannover.

Financial terms of the agreement are not being disclosed.

"We are excited about the potential of our alliance with evocatal, who combine an impressive entrepreneurial spirit with a deep understanding of developing innovative enzymes for the fine chemicals industry", said Thomas Fischer, CEO, EUCODIS Bioscience.

Dr. Thorsten Eggert, CEO of evocatal, agreed: "We also see Eucodis as a strong, technology-driven company with a solid portfolio of branded products. By forming this partnership we truly join our forces allowing the partners to significantly broaden their offerings to existing and to new customers".

Dr. Michael Puls, CMO of evocatal, commented on the alliance: "We really team up in this process to significantly increase our customers' benefit. Customers have now access to a larger enzyme portfolio through a single channel and also to a much broader service network."

"We can thus provide more expertise in biocatalysis," added Dr. Bhupinder Hundle, Senior VP Marketing and Sales, EUCODIS Bioscience. "This supports both of us in our continuous striving to provide the best possible service."

evocatal and EUCODIS Bioscience jointly look forward to a great teamwork and fruitful cooperation to serve their customers' needs.

About EUCODIS Bioscience

EUCODIS Bioscience provides enzymes to the chemical, health care, and other industries, and offers custom-engineering and custom-manufacturing services.

Customers use EUCODIS Bioscience' enzymes and services to make their manufacturing processes more efficient and cleaner and to introduce products with superior properties. The Company's technology of in vivo-recombination is a proven tool for the directed evolution of enzymes that perform to customers' specific requirements.

Enzymes are proteins that catalyze highly specific chemical reactions, offering a safer, cleaner, and competitive alternative to traditional chemistry. They are at the center of industrial, or "white" biotechnology, a fast growing industry segment with sales in excess of EUR100 billion.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.

For more information, please visit

evoxx technologies GmbH

evocatal GmbH is a Germany-based industrial biotech company, specialized in the development of biocatalysts and enzyme-based chemical processes.

The name evocatal connects the terms 'evolution' and 'catalysis' and stands for the core competencies of the Company: the tailor-made development of new enzymes for use in the production of complex low-molecular weight compounds and fine chemicals for the pharmaceutical industry.

evocatal has built up a portfolio of proprietary biocatalysts (evozymes®) that is continuously broadened by innovative new developments meeting the demands in industry. The company furthermore offers the development of enzymes and enzyme production systems as contract service.

Furthermore evocatal has commercialized the first fluorescent protein for anaerobic applications in biomedical research and development.

For more information, please visit